review_heavy
Review literature is very dense relative to primary central evidence.
supportedtopmoderate inflation risk
Candida
inflammatory bowel disease
Candida is an interesting but still moderate-confidence signal in inflammatory bowel disease.
Candida shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
candida
Credibility score
50
Human translation
3/5
Reproducibility
5/5
Novelty
2/5
Actionability
3/5
Credibility 50Human translation 3/5Reproducibility 5/5Novelty 2/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
Main caveats
- retrieval noise or disease-specificity issues may remain
Internal review flags
1 flagsPrimary central evidence
11 papersFungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease.
2015Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal microbiota dysbiosis in IBD.
2017Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease.
2019Journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Immune regulation by fungal strain diversity in inflammatory bowel disease.
2022Nature
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α.
2022Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the Fungal Microbiome in Ulcerative Colitis.
2023Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.
2024Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease.
2023Microorganisms
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors.
2025Acta dermato-venereologica
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mycobiota dynamics in inflammatory bowel disease: Fungal biomarkers and Clostridioides difficile co-infection.
2025Microbial pathogenesis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal Mycobiota in Patients with Inflammatory Bowel Diseases and Extraintestinal Manifestations.
2024Gut microbes reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
9 papersHuman colonic mucus is a reservoir for antimicrobial peptides.
2013Journal of Crohn's & colitis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Vaginal microbiota in pregnant women with inflammatory rheumatic and inflammatory bowel disease: A matched case-control study.
2021Mycoses
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Absence of Oral Opportunistic Infections in Patients with Inflammatory Bowel Disease Receiving Anti-TNF-α and Anti-Integrin-α4β7 Therapy.
2022Dentistry journal
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation.
2023Cell reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
2024Dermatology and therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Disability, Physical Activity, and Their Correlates in Patients With Inflammatory Bowel Disease: A Portuguese Cross-Sectional Survey.
2024Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Candida tropicalis-derived vitamin B3 exerts protective effects against intestinal inflammation by promoting IL-17A/IL-22-dependent epithelial barrier function.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Brodalumab: Six-Year US Pharmacovigilance Report.
2025Dermatology and therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies.
2025Rheumatology (Oxford, England)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
25 papersTherapy- and non-therapy-dependent infectious complications in inflammatory bowel disease.
2009Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Inflammation and gastrointestinal Candida colonization.
2011Current opinion in microbiology
Relevant review or meta-analysis for the signal-disease area.
An immunological link between Candida albicans colonization and Crohn's disease.
2015Critical reviews in microbiology
Relevant review or meta-analysis for the signal-disease area.
Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.
2015World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
2016BMC health services research
Relevant review or meta-analysis for the signal-disease area.
Clinical Trial and Registry Data.
2018Current problems in dermatology
Relevant review or meta-analysis for the signal-disease area.
Fungal infections in patients with inflammatory bowel disease: A systematic review.
2018Mycoses
Relevant review or meta-analysis for the signal-disease area.
Guselkumab for the Treatment of Psoriasis.
2018BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Relevant review or meta-analysis for the signal-disease area.
The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease.
2018Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
[Microbiota and inflammatory bowel disease: an update.].
2018Recenti progressi in medicina
Relevant review or meta-analysis for the signal-disease area.
Review article: fungal alterations in inflammatory bowel diseases.
2019Alimentary pharmacology & therapeutics
Relevant review or meta-analysis for the signal-disease area.
The daily impact of COVID-19 in gastroenterology.
2020United European gastroenterology journal
Relevant review or meta-analysis for the signal-disease area.
Fungi of the human gut microbiota: Roles and significance.
2021International journal of medical microbiology : IJMM
Relevant review or meta-analysis for the signal-disease area.
Fungal microbiome in inflammatory bowel disease: a critical assessment.
2022The Journal of clinical investigation
Relevant review or meta-analysis for the signal-disease area.
Mycobiome and Inflammatory Bowel Disease: Role in Disease Pathogenesis, Current Approaches and Novel Nutritional-based Therapies.
2023Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023Digestion
Relevant review or meta-analysis for the signal-disease area.
Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease.
2022Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Immunoglobulins at the interface of the gut mycobiota and anti-fungal immunity.
2023Seminars in immunology
Relevant review or meta-analysis for the signal-disease area.
Candida spp. in Human Intestinal Health and Disease: More than a Gut Feeling.
2023Mycopathologia
Relevant review or meta-analysis for the signal-disease area.
Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease.
2023Journal of fungi (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.
2024Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Oral Anti-Inflammatory and Symbiotic Effects of Fermented Lingonberry Juice-Potential Benefits in IBD.
2024Nutrients
Relevant review or meta-analysis for the signal-disease area.
Role of Candida species in pathogenesis, immune regulation, and prognostic tools for managing ulcerative colitis and Crohn's disease.
2024World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
2025Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.
2026Gut microbes
Relevant review or meta-analysis for the signal-disease area.